Production (Stage)
PharmaRoth Labs, Inc.
ROTH
$0.00
$0.000.00%
OTC PK
| 03/31/2011 | 12/31/2010 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 269.21% | -78.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 516.53% | -78.32% | |||
| Operating Income | -102.89% | 78.32% | |||
| Income Before Tax | -85.98% | 75.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -85.98% | 75.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -85.98% | 75.72% | |||
| EBIT | -102.89% | 78.32% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -75.00% | 76.47% | |||
| Normalized Basic EPS | -66.67% | 72.73% | |||
| EPS Diluted | -75.00% | 76.47% | |||
| Normalized Diluted EPS | -66.67% | 72.73% | |||
| Average Basic Shares Outstanding | 8.05% | -0.36% | |||
| Average Diluted Shares Outstanding | 8.05% | -0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||